Lakefront Biotherapeutics NV: Arthritis trials

The registry lists 10 Arthritis studies with Lakefront Biotherapeutics NV as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 2 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateCompletedNCT04577781Phase 2Results posted
• Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisCompletedNCT03926195Phase 2Results posted
• Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedNCT02065700Phase 2Results posted
• Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)CompletedNCT01894516Phase 2Results posted
• Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)CompletedNCT01888874Phase 2Results posted
• An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.TerminatedNCT03320876Phase 2
• A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic ArthritisCompletedNCT03101670Phase 2
• Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01668641Phase 2
• Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01384422Phase 2
• GLPG0259 in Methotrexate-refractory Rheumatoid ArthritisCompletedNCT01211249Phase 2